Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD)
CUSIP: M47238148
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Ordinary Shares, NIS 1.80 par value per share
- Shares outstanding
- 5,591,387
- Total 13F shares
- 75,987
- Share change
- +20,111
- Total reported value
- $140,174
- Price per share
- $1.86
- Number of holders
- 14
- Value change
- +$46,243
- Number of buys
- 7
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP M47238148?
CUSIP M47238148 identifies GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP M47238148:
Top shareholders of GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Allen Baharaff |
13D/G
|
— |
2.6%
|
44,128
|
$60,455 | $0 | 31 Dec 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.45%
|
25,194
|
$36,279 | — | 31 Mar 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.2%
|
11,126
|
$16,000 | — | 31 Mar 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.2%
|
11,019
|
$15,867 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.13%
|
7,385
|
$10,634 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
1,104
|
$1,589 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
16
|
$23 | — | 31 Mar 2025 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
14
|
$20 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
9
|
$13 | — | 31 Mar 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
5
|
$7 | — | 31 Mar 2025 | |
| Allworth Financial LP |
13F
|
Company |
0%
|
2
|
$4 | — | 31 Mar 2025 | |
| ELEVATION WEALTH PARTNERS, LLC |
13F
|
Company |
0%
|
1
|
$2 | — | 31 Mar 2025 | |
| Dogwood Wealth Management LLC |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2025 |
Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) as of Q2 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.